Ocumension Therapeutics Future Growth
Future criteria checks 2/6
Ocumension Therapeutics is forecast to grow earnings and revenue by 73.7% and 39.6% per annum respectively. EPS is expected to grow by 75.1% per annum. Return on equity is forecast to be -0.3% in 3 years.
Key information
73.7%
Earnings growth rate
75.1%
EPS growth rate
| Pharmaceuticals earnings growth | 12.9% |
| Revenue growth rate | 39.6% |
| Future return on equity | -0.3% |
| Analyst coverage | Low |
| Last updated | 13 Aug 2024 |
Recent future growth updates
Recent updates
Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results
Aug 15
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now
Jun 13Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable
Apr 29Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation
Mar 14Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates
Aug 29We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely
Jul 13Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?
Jun 02We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate
Jan 20We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate
Sep 27Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?
Jan 23
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,287 | 76 | 167 | N/A | 3 |
| 12/31/2025 | 770 | -148 | 104 | N/A | 3 |
| 12/31/2024 | 466 | -241 | -7 | N/A | 2 |
| 6/30/2024 | 310 | -323 | N/A | N/A | N/A |
| 3/31/2024 | 278 | -351 | N/A | N/A | N/A |
| 12/31/2023 | 246 | -380 | -540 | -178 | N/A |
| 9/30/2023 | 227 | -399 | -561 | -223 | N/A |
| 6/30/2023 | 208 | -418 | -582 | -269 | N/A |
| 3/31/2023 | 184 | -411 | -546 | -235 | N/A |
| 12/31/2022 | 159 | -403 | -511 | -201 | N/A |
| 9/30/2022 | 124 | -393 | -615 | -165 | N/A |
| 6/30/2022 | 90 | -383 | -720 | -129 | N/A |
| 3/31/2022 | 73 | -322 | -791 | -163 | N/A |
| 12/31/2021 | 56 | -260 | -862 | -197 | N/A |
| 9/30/2021 | 44 | -426 | -760 | -232 | N/A |
| 6/30/2021 | 32 | -593 | -659 | -267 | N/A |
| 3/31/2021 | 23 | -1,429 | -588 | -240 | N/A |
| 12/31/2020 | 13 | -2,265 | -517 | -213 | N/A |
| 9/30/2020 | 8 | -2,540 | -407 | -173 | N/A |
| 6/30/2020 | 2 | -2,816 | -297 | -133 | N/A |
| 3/31/2020 | 1 | -2,064 | -203 | -120 | N/A |
| 12/31/2019 | 0 | -1,312 | -109 | -108 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1477 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1477 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1477 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1477's revenue (39.6% per year) is forecast to grow faster than the Hong Kong market (7.4% per year).
High Growth Revenue: 1477's revenue (39.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1477 is forecast to be unprofitable in 3 years.